Staff Profile

Qualifications 

BSc (hons) Biochemistry, University of York

PhD Neuroimmunology, University of Glasgow 

PGCert Academic Practice, University of Glasgow 

Previous Positions 

Academic

Lecturer, University of Glasgow 

Research Fellow, University of Bergen

Postdoctoral Researcher, King's College London

Research Associate, University of Glasgow

Industrial

Principal Scientist, C4X Discovery Ltd

Professional Societies 

Royal Society of Biology 

British Pharmacological Society 

Other roles

Guest lecturer, King's College London (MSc Neuroscience)

Editorial board, BMC research notes

Review editor, Frontiers in Pharmacology 

Member, Deep Dementia Phenotyping Network (DEMON)

Organising team/ Guest/ Contributor #LTHEchat (learning and teaching in HE tweetchat) 

I am the module leader for the following modules:  

BMS3016, Science Communication

PED1003, Pharmacology 

I also am involved in teaching across several modules including: 

CMB1004, Cell Biology 

CMB1005/6, Practical Skills in Biomedical & Biomolecular Sciences

PED1003, Pharmacology

BMS2002, Cell Biology & Disease 

BMS3016, Science Communication 

Student Supervision 

Supervision of undergraduate and postgraduate research project students 

Teaching & Scholarship Interests 

Gamification and games-based learning 

Feedback standardisation and student feedback literacy 

Digital education/ technology enhanced learning 

Neurodiversity

My current research interests focus on elucidating the molecular mechanisms that underpin neurodegenerative diseases and how this knowledge can be leveraged to provide novel therapeutic strategies. 

• Functional genomics / transcriptomics 
• Drug repositioning / discovery 
• Disease modelling in vitro 
• Target identification and validation
• Assay development and high-throughput compound screening 

• Articles

  • Killick R, Elliott C, Ribe E, Broadstock M, Ballard C, Aarsland D, Williams G. Neurodegenerative Disease Associated Pathways in the Brains of Triple Transgenic Alzheimer’s Model Mice Are Reversed Following Two Weeks of Peripheral Administration of Fasudil. International Journal of Molecular Sciences 2023, 24(13), 11219.
  • Glennon EB, Lau DHW, Gabriele RMC, Taylor MF, Troakes C, Opie-Martin S, Elliott C, Killick R, Hanger DP, Perez-Nievas BG, Noble W. Bridging integrator 1 protein loss in Alzheimer’s disease promotes synaptic tau accumulation and disrupts tau release. Brain Communications 2020, 2(1), fcaa011.
  • Engelhardt B, Holze J, Elliott C, Baillie GS, Kschischo M, Frohlich H. Modelling and Mathematical Analysis of the M2-Receptor Dependent Joint Signaling and Secondary Messenger Network in CHO Cells. Mathematical Medicine & Biology 2018, 35(3), 279-297.
  • Yalla K, Elliott C, Day JP, Findlay J, Barratt S, Hughes ZA, Wilson L, Whiteley E, Popiolek M, Li Y, Dunlop J, Killick R, Adams DR, Brandon NJ, Houslay MD, Hao B, Baillie GS. FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Molecular Psychiatry 2018, 23, 1278-1286.
  • Sellers KJ, Elliott C, Jackson J, Ghosh A, Ribe E, Rojo-Sanchís A, Jarosz-Griffiths HH, Watson IA, Xia W, Semenov M, Morin P, Hooper NM, Porter R, Preston J, Al-Shawi R, Baillie GS, Lovestone S, Cuadrado A, Harte M, Simons P, Srivastava DP, Killick R. Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil. Alzheimer’s and Dementia 2018, 14(3), 306-317.
  • Elliott C, Rojo A, Ribe E, Broadstock M, Xia W, Morin P, Semenov M, Baillie G, Cuadrado A, Al-Shawi R, Ballard CG, Simons P, Killick R. A role for APP in Wnt signalling links synapse loss with β-amyloid production. Translational Psychiatry 2018, 8, 179.
  • Ashton NJ, Hye A, Leckey CA, Jones AR, Gardner A, Elliott C, Wetherell JL, Lenze EJ, Killick R, Marchant NL. Plasma REST: a novel candidate biomarker of Alzheimer’s disease is modified by psychological intervention in an at risk population. Translational Psychiatry 2017, 7(6), e1148.
  • Tankou S, Ishii K, Elliott C, Yalla KC, Day JP, Furukori K, Kubo K, Brandon NJ, Tang Q, Hayward G, Nakajima K, Houslay MD, Kamiya A, Baillie GS, Ishizuka K, Sawa A. SUMOylation of DISC1: A Potential Role in Neural Progenitor Proliferation in the Developing Cortex. Molecular Neuropsychiatry 2016, 2(1), 20-27.
  • McGirr A, Lipina TV, Mun H, Georgiou J, Al-Amri AH, Ng E, Zhai D, Elliott C, Cameron RT, Mullins JGL, Liu F, Baillie GS, Clapcote SJ, Roder JC. Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition. Neuropsychopharmacology 2016, 41(4), 1080-1092.
  • Allan D, Fairlie-Clarke K, Elliott C, Schuh C, Barnett SC, Lassmann H, Linington C, Jiang H. Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system. Acta Neuropathologica Communications 2016, 4(1), 75.
  • Roscoe RB, Elliott C, Zarros A, Baillie GS. Non-genetic therapeutic approaches to Canavan disease. Journal of the Neurological Sciences 2016, 366, 116-124.
  • Dachtler J, Elliott C, Rodgers RJ, Baillie GS, Clapcote SJ. Missense mutation in DISC1 C-terminal coiled-coil has GSK3β signaling and sex-dependent behavioral effects in mice. Scientific Reports 2016, 6, 18748.
  • Al-Nimer F, Elliott C, Bergman J, Khademi M, Dring AM, Aeinehband S, Bergenheim TR, Christensen J, Sellebjerg F, Svenningsson A, Linington C, Olsson T, Piehl F. Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurology – Neuroimmunology & Neuroinflammation 2016, 3(1), e191.
  • Byrne AM, Elliott C, Hoffmann R, Baillie GS. The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus. FEBS Letters 2015, 589(6), 750-755.
  • Lindner M, Thuemmler K, Arthur A, Brunner S, Elliott C, McElroy D, Mohan H, Williams A, Edgar JM, Schuh C, Stadelmann C, Barnett SC, Lassmann H, Muecklisch S, Mudaliar M, Schaeren-Wiemers N, Meinl E, Linington C. Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of proinflammatory environment by FGF9. Brain 2015, 138(7), 1875-1893.
  • Mohan H, Friese A, Albrecht S, Krumbholz M, Elliott CL, Arthur A, Menon R, Farina C, Junker A, Stadelmann C, Barnett SC, Huitinga I, Wekerle H, Hohlfeld R, Lassmann H, Kuhlmann T, Linington C, Meinl E. Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. Acta Neuropathologica Communications 2014, 2(1), 178.
  • Martin TP, Hortigon-Vinagre M, Findlay JE, Elliott C, Currie S, Baillie GS. Targeted disruption of the heat shock protein 20-phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy. FEBS Open Bio 2014, 4(1), 923-927.
  • Elliott C, Lindner M, Arthur A, Brennan K, Jarius S, Hussey J, Chan A, Stroet A, Olsson T, Willison H, Barnett SC, Meinl E, Linington C. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012, 135(6), 1819-1833.
  • Brennan KM, Galban-Horcajo F, Rinaldi S, O'Leary CP, Goodyear CS, Kalna G, Arthur A, Elliott C, Barnett S, Linington C, Bennett JL, Owens GP, Willison HJ. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. Journal of Neuroimmunology 2011, 238(1).